Straumann stock trades softer as market awaits H1 2026 earnings
Published on 08/18/2026 at 20:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Straumann Holding AG (CH0012280076) stock is trading modestly lower on August 18, 2026 as investors position ahead of the company’s half-year 2026 earnings report due on August 19, 2026. Per a recent consensus preview, the market is looking for H1 2026 revenue of CHF 1,375 million and EBIT of CHF 342.6 million, which would both come in above the prior-year period.
Shares ease before H1 2026 report
According to a Cboe-based quote page, Straumann shares last traded at CHF 99.64 on August 18, 2026, down 0.76% on the day and 1.86% since the beginning of 2026. This market data snapshot shows the stock consolidating just below the CHF 100 mark after recent swings in the Swiss large-cap space.
A separate overview of Straumann’s sector peers in Europe indicates that the stock’s home-market line on August 18, 2026 was quoted at EUR 105.60, showing a five-day performance of -1.26% and a year-to-date move of -2.82%. The Tradegate quote overview underscores that Straumann has lagged some medical-prosthesis peers year to date despite ongoing expectations for solid earnings growth.
Consensus points to continued growth
An earnings preview published on August 18, 2026 outlines what analysts expect Straumann to deliver when it reports H1 2026 results on August 19, 2026. The consensus table highlights forecast revenue of CHF 1,375 million for H1 2026 compared with CHF 1,348 million in H1 2025, implying organic growth of 7.4% after 10.2% organic growth in the prior-year period.
On the profitability side, the same H1 2026 preview points to expected EBIT of CHF 342.6 million versus CHF 329.6 million in H1 2025, with the EBIT margin projected to improve to 24.9% from 24.4%. The core EBIT margin is forecast at 25.4% in H1 2026 compared with 26.6% in H1 2025, indicating that while absolute earnings are anticipated to rise, normalized profitability may face some pressure versus last year’s very strong baseline.
Net income is expected to grow as well, with consensus calling for H1 2026 reported profit of CHF 247.2 million compared with CHF 238.2 million in H1 2025. Core net income is projected at CHF 249.5 million for H1 2026 against CHF 265.7 million a year earlier, suggesting that below-the-line items and adjustments could make the quality and composition of earnings a key talking point once Straumann releases its detailed half-year figures.
Volatility reflects broader Swiss market
Recent commentary on Swiss blue chips notes that Straumann shares have traded in negative territory along with several other major Swiss names, with intraday losses in the range of 1% to 2% reported for the session around August 18, 2026. A morning market wrap cites Straumann among stocks that weakened, reflecting a softer tone in the Swiss equity market ahead of a busy stretch of earnings updates.
That backdrop matters for Straumann because the stock has delivered a small negative year-to-date performance at CHF 99.64, while dental and medical technology peers in Europe have been more mixed. A Swiss listing overview lists a last close on August 18, 2026 at CHF 99.66, a five-day change of -0.79% and a year-to-date move of -4.49% versus a 6.63% gain over the prior twelve months, highlighting how Straumann’s 2026 consolidation comes after a strong run-up in the preceding year.
For investors, those figures mean that much of the focus heading into the August 19, 2026 release is on Straumann’s ability to convert mid-single-digit organic top-line growth into sustained margin resilience. Any deviation from the forecast EBIT margin of 24.9% or organic revenue growth of 7.4% in H1 2026 compared with the 10.2% pace in H1 2025 could quickly influence sentiment in a stock that has already given back some of its earlier gains.
Implant systems remain core driver
Straumann’s core business remains premium dental implant systems and related regenerative solutions, which are central to its growth narrative in both developed and emerging markets. Based on public information, the Straumann brand covers a wide portfolio of implant lines designed for different indications and bone conditions, complemented by prosthetic components and digital workflows that enable dentists and oral surgeons to plan and place implants more efficiently.
Over recent reporting periods, investors have closely watched how the mix between premium and value implant offerings affects Straumann’s revenue growth and margins. A higher share of premium solutions tends to support margins but can be sensitive to macro cycles, while value-oriented products help expand Straumann’s addressable market in cost-sensitive regions. As H1 2026 results approach, the composition of growth across these product categories will likely be as important to the market as the headline revenue figure of CHF 1,375 million expected by consensus.
Straumann stock and current valuation snapshot
In addition to the Cboe line at CHF 99.64 on August 18, 2026, an international overview page shows Straumann quoted on the Swiss Exchange with the last close the same day at CHF 99.66. That page also reports a five-day performance of -0.79% and a year-to-date move of -4.49%, while the change since the beginning of the previous twelve-month period stands at +6.63%. The Swiss listing data underline how Straumann stock combines short-term weakness with longer-term gains, a pattern that often reflects profit-taking after a strong prior-year rally.
For US-based investors following Straumann via its over-the-counter instrument, a quote page for the SAUHY American Depositary Receipt shows the ADR trading in the low-teens dollar range on August 18, 2026, with a high and open price of $12.47 on the day. This ADR snapshot offers an alternative way to track Straumann’s performance in US dollars, though volumes tend to be lighter than in Zurich.
Fact box
Company: Straumann Holding AG
ISIN: CH0012280076
Ticker: STMN
Exchange: SIX Swiss Exchange (primary listing), Cboe Europe (secondary quote)
Price (as of August 18, 2026, end of day Swiss session): CHF 99.66
Market cap: not specified in the cited intraday sources
Sector / Industry: Medical technology / Dental implants and prosthetics
Index membership: Swiss large-cap universe (SMI-related context based on Swiss equity coverage)
